{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:19Z","timestamp":1790014819746,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>This chapter focuses on the position of botulinum toxin type A in the treatment pathway for overactive bladder (OAB) and neurogenic lower urinary tract dysfunction associated with neurogenic detrusor overactivity (NDO), and the recommendations of the major international guideline groups. Recommendations of different guideline groups may vary, especially when evidence is weak, often because of differences in methodology and panel composition.<\/jats:p><jats:p>Relevant guidelines from the European Association of Urology, American Urological Association, and the UK National Institute for Care and Clinical Excellence were reviewed, and the recommendations that form the basis of the treatment algorithms have been discussed. Any differences between guidelines have been highlighted and special emphasis made on the position of botulinum toxin type A in these pathways.<\/jats:p><jats:p>In all the reviewed guidelines, botulinum toxin type A is recommended, alongside sacral nerve neuromodulation, to treat OAB and NDO in patients who have failed oral therapy. The evidence base is consistent, but further evidence is required regarding optimal dosing regimens and injection technique. <jats:italic>Neurourol. Urodynam. 33:S21\u2013S25, 2014<\/jats:italic>. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.22631","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T15:48:02Z","timestamp":1404834482000},"source":"Crossref","is-referenced-by-count":46,"title":["Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)"],"prefix":"10.1002","volume":"33","author":[{"given":"Arjun","family":"Nambiar","sequence":"first","affiliation":[{"name":"Department of Urology Morriston Hospital Swansea United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Urology Morriston Hospital Swansea United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"key":"e_1_2_4_2_1","unstructured":"LucasMG BoschRJ CruzF et al. EAU guidelines on urinary incontinence. Available at:http:\/\/www.uroweb.org\/guidelines\/online\u2010guidelines\/."},{"key":"e_1_2_4_3_1","unstructured":"PannekJ St\u00f6hrerM BlokB et al. EAU guidelines on neurogenic lower urinary tract dysfunction 2011. Available at:http:\/\/www.uroweb.org\/gls\/pdf\/17_Neurogenic%20LUTS.pdf."},{"key":"e_1_2_4_4_1","unstructured":"OelkeM BachmannA DescazeaudA et al. EAU Guidelines on the treatment and follow\u2010up of non\u2010neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Available at:http:\/\/www.uroweb.org\/gls\/pdf\/13_Male_LUTS_LR.pdf."},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.079"},{"key":"e_1_2_4_6_1","unstructured":"National Institute of Clinical Excellence (NICE). CG171 Urinary Incontinence in Women: Full Guideline 2013."},{"key":"e_1_2_4_7_1","unstructured":"National Institute of Clinical Excellence (NICE). Urinary incontinence in neurological disease: Management of lower urinary tract dysfunction in neurological disease (CG148) 2012."},{"key":"e_1_2_4_8_1","unstructured":"National Institute of Clinical Excellence (NICE). Mirabegron for treating symptoms of overactive bladder (TA290) 2013."},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-10-199505150-00003"},{"key":"e_1_2_4_10_1","first-page":"CD003195","article-title":"Urodynamic studies for management of urinary incontinence in children and adults","volume":"1","author":"Glazener CM","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37254-3"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.081"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta14400"},{"key":"e_1_2_4_14_1","volume-title":"Nonsurgical treatments for urinary incontinence in adult women: Diagnosis and comparative effectiveness","author":"Shamliyan T","year":"2012"},{"key":"e_1_2_4_15_1","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","volume":"1","author":"Madhuvrata P","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.07.032"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.04.001"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208872"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.021"},{"key":"e_1_2_4_23_1","doi-asserted-by":"crossref","unstructured":"NittiVW SussmanDO RadomskiSB et al.2013; OnabotulinumtoxinA in patients with overactive bladder and urinary incontinence: Consistent effect over repeat treatment. 2013: Poster MP51.","DOI":"10.1016\/j.juro.2013.02.2721"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22631","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:39:31Z","timestamp":1696005571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":22,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/nau.22631"],"URL":"https:\/\/doi.org\/10.1002\/nau.22631","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}